Estrogen replacement therapy and fibrocystic breast disease in postmenopausal women.
The association between estrogen replacement therapy and fibrocystic breast disease was assessed in a hospital-based case-control study undertaken in Connecticut from 1979 to 1981. The cases were 143 postmenopausal women with biopsy-confirmed fibrocystic breast disease, and the controls were 355 postmenopausal women with other surgical conditions. Use of estrogen replacement therapy was positively associated with fibrocystic breast disease; the odds of disease increased with duration of use, reaching an approximately fivefold excess odds for those who had taken menopausal estrogens for 10 or more years. There was no evidence that the positive association between estrogen replacement therapy and the occurrence of fibrocystic breast disease could be explained by differential medical care utilization or other possible risk factors of biopsied fibrocystic breast disease.
D000328:Adult; D000368:Aged; D003237:Connecticut; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005348:Fibrocystic Breast Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D010173:Palpation; D012044:Regression Analysis; D012306:Risk; D013997:Time Factors
D004967:Estrogens